Tempus: Stemline Therapeutics to Deploy Tempus Next's AI-Enabled Care Pathway Intelligence Platform

What You Should Know: - Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). - The partnership will leverage Tempus' Next platform, an AI-enabled care pathway intelligence tool, to ... Read More